R&D channel feed

Cor­rect­ed: Cardiff’s stock jumps af­ter shar­ing promis­ing PhII da­ta for its PLK1 in­hibitor in pan­cre­at­ic can­cer

Last year

Gilead stops an­oth­er CD47 study, this time in acute myeloid leukemia

Last year

First shot at pan-coro­n­avirus vac­cine dis­ap­points in VBI Vac­cines study

Last year

Ab­b­Vie drops Cari­bou part­ner­ship on gene-edit­ed CAR-T ther­a­py

Last year
Cell/Gene Tx

Pli­ant shares spike on ex­plorato­ry study re­sults of lead drug in chron­ic liv­er dis­ease

Last year

Io­n­is plans NDA fil­ing for first in­de­pen­dent drug af­ter pos­i­tive da­ta read­out in rare ge­net­ic dis­or­der

Last year

Omega Ther­a­peu­tic­s' epige­nom­ic med­i­cines re­duce MYC ex­pres­sion by 55% in ear­ly study of can­cer pa­tients

Last year

Up­dat­ed: Roivant’s FcRn an­ti­body for au­toim­mune dis­ease shows ear­ly po­ten­tial in study with healthy sub­jects

Last year

For decades, can­cer drug de­vel­op­ers have fo­cused on in­hi­bi­tion. Now, a GV-backed start­up is eye­ing ac­ti­va­tion

Last year
Startups

No­var­tis ra­di­oli­gand tri­umphs in a first-line PhI­II tri­al re­cruit­ing pa­tients with rare neu­roen­docrine tu­mors

Last year

Ab­b­Vie ful­ly ditch­es I-Mab's CD47 drug af­ter ini­tial 2022 pull­back from $1B+ bet

Last year
Deals
Pharma

Mor­phic’s stock falls af­ter new da­ta sug­gest low­er-than-ex­pect­ed ef­fi­ca­cy for its ul­cer­a­tive col­i­tis pill 

Last year

In­di­a's Glen­mark Phar­ma­ceu­ti­cals di­vests 75% stake in its API man­u­fac­tur­ing sub­sidiary

Last year
Manufacturing

As­traZeneca, Dai­ichi Sankyo eye first ap­proval for TROP2 drug af­ter PhI­II breast can­cer suc­cess

Last year

Tra­vere Ther­a­peu­tics just miss­es on con­fir­ma­to­ry study for kid­ney dis­ease drug, stock plum­mets

Last year

Elon Musk's brain-com­put­er pro­gram be­gins re­cruit­ing paral­y­sis pa­tients

Last year
Pharma
FDA+

Seelos' stock plunges by over 75% af­ter ke­t­a­mine drug for sui­cide pre­ven­tion fails a PhII tri­al

Last year

Rel­ma­da’s ma­jor de­pres­sion drug shows PhI­II promise in a fresh batch of pa­tients

Last year

UCB's Eu­rope-ap­proved IL-17 au­toim­mune drug hits FDA de­lay

Last year
FDA+

Taysha stops de­vel­op­ing a gene ther­a­py amid de­bate over FDA’s stance on ul­tra-rare tri­als

Last year
Cell/Gene Tx

MRM open to part­ner­ships af­ter lead can­di­date im­press­es in PhI­Ia ul­cer­a­tive col­i­tis tri­al

Last year

Kin­nate lays off 70% of em­ploy­ees, shaves pipeline to fo­cus on CDK4 and pan-RAF in­hibitor

Last year
People

No­var­tis hands back PD-1 in­hibitor to BeiGene af­ter reg­u­la­to­ry hur­dles

Last year
Deals
FDA+

Ex­clu­sive: Backed by for­mer Google CEO’s VC, a Col­orado biotech hatch­es plat­form to evolve de­graders

Last year
Financing
Startups
First page Previous page 70717273747576 Next page Last page
A service from the Financial Times